UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen published final five-year follow-up results from the Olympus study of JELMYTO in low-grade upper tract urothelial cancer in Therapeutic Advances in Urology. Among 41 complete responders, median duration of response was 47.8 months; in the 20-patient long-term cohort, 75% remained event-free and no progression to high-grade disease was observed.
Key figures
- Drug Name
- JELMYTO (mitomycin) for pyelocalyceal solution
- Phase Of Trial
- Phase 3 (Olympus) five-year long-term follow-up
- Event free rate
- 75% (15/20)
- Median followup months
- 28.1
- Progression to high grade
- No
- Complete response patients
- 41
- Long term followup patients
- 20
- Long term median followup months
- 53.3
- Median duration of response months
- 47.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.